Sinclair plans whole-body rejuvenation drug trial for XPrize

David Sinclair plans to launch human tests of an oral reprogramming drug as part of the XPrize Foundation's $101 million competition. The grand prize rewards teams that show a 10-year relative age improvement after one year of treatment. Sinclair confirmed the bid seeks evidence for age restoration in humans.